Effects of GLP‐1 Receptor Agonists on Paediatric Population in a Real World Setting

Documenti analoghi

• Efficacy of Tirzepatide Dual GIP / GLP ‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study
  di: Ahmed Y. Azzam, et al.
  Pubblicazione: (2025)
• The Gastrointestinal Safety of Orforglipron, a GLP ‐1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta‐Analysis of Randomized Controlled Trials
  di: Ahmed W. Hageen, et al.
  Pubblicazione: (2026)
• Efficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta‐Analysis
  di: Abdur Rafay Bilal, et al.
  Pubblicazione: (2026)
• Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta‐Analysis of Clinical Trials
  di: Celina R. Andonie, et al.
  Pubblicazione: (2025)
• Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials
  di: Ayah Abulehia, et al.
  Pubblicazione: (2026)